Dong-A Socio Holdings is absorbing its 100% subsidiary Dong-A Pharmaceutical to become an operating holding company, expanding the group's investment capacity according to analysis by NICE Credit Rating published on the 24th. The merger was disclosed on the 23rd and follows small-scale merger procedures without new share issuance. NICE Credit Rating assessed that the holding company previously utilized Dong-A Pharmaceutical's cash flow generation through limited means such as dividends, but the absorption merger secures autonomy in fund management, creating possibilities for expanded investments including new business ventures, mergers and acquisitions, and subsidiary support at the group level.
Dong-A Socio Holdings Sets Merger Contract Date for the 27th with October 1st Completion
The merger contract date is scheduled for the 27th with completion planned for October 1st. The surviving company Dong-A Socio Holdings will change its name to Dong-A Pharmaceutical after the merger. The transaction proceeds as a non-capital increase merger without issuing new merger shares under small-scale merger procedures.
NICE Credit Rating Maintains A Stable Rating After Merger Analysis
NICE Credit Rating maintained Dong-A Socio Holdings' long-term credit rating at A (stable). Kwon Jun-sung, principal researcher at NICE Credit Rating Corporate Rating Office 4, stated that the company previously utilized Dong-A Pharmaceutical's cash flow generation capacity through limited means such as dividends, but the absorption merger secures autonomy in fund management. The agency judged that credit impact is limited as there are no substantial changes to financial stability, cash generation capacity, and business portfolio on a consolidated financial statement basis before and after the merger.
Company States Operating Holding Company Conversion Aims to Secure New Growth Investment Funds
The company presented merger objectives including securing investment funds for new growth engines through operating holding company conversion, simplifying governance structure, and resolving holding company discount factors arising from duplicate subsidiary listing. Kwon analyzed that possibilities exist for expanded investments at the group level including new business ventures, mergers and acquisitions, and subsidiary support.
FAQ
When will Dong-A Socio Holdings complete the merger with Dong-A Pharmaceutical?
The merger contract date is the 27th with completion scheduled for October 1st. The surviving company will change its name to Dong-A Pharmaceutical after the merger.
What credit rating did NICE Credit Rating assign to Dong-A Socio Holdings after the merger analysis?
NICE Credit Rating maintained the long-term credit rating at A (stable), judging that credit impact is limited as there are no substantial changes to financial stability and cash generation capacity on a consolidated basis before and after the merger.
